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The neurons in the developing mammalian brain are susceptible to antiepileptic drug (AED)
effects. It is known that later in life deficits in cognitive performance as well as psychi-
atric deficits can manifest after early AED exposure. The extent of these deficits will be
addressed. This review will attempt to draw parallels between the existent animal models
and human studies. Through analysis of these studies, important future research will be
elucidated and possible new and emerging therapies will be discussed.
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INTRODUCTION
The developing brain is exquisitely sensitive to drug-induced per-
turbations of the chemical environment of neurons. Exposure
to these agents during mammalian brain maturation has been
associated with alterations in cognitive performance later in life
including risk factors for neuropsychiatric outcomes. The extent
to which the preclinical animal findings translate to the human
data will be discussed.
The time course of brain development in experimental ani-
mals and the manner in which that time course maps onto brain
development in humans are important to research design and
interpretation of findings. Neurological and psychiatric abnormal-
ities can occur following developmental exposure to antiepileptic
drugs (AEDs). Unfortunately, the sensitive periods for toxicity to
various drugs are not certain in humans. Research on fetal alcohol
syndrome may be able to provide a vital link to inform studies on
AEDs. The mechanisms by which early life drug exposure alters
nervous system function in later developmental phases will be
discussed.
Through animal models and through analysis of clinical
outcomes in humans the current state of knowledge and key
targets for future research can be elucidated. It is impor-
tant to evaluate novel therapeutic paradigms to minimize
AEDs effect on the developing brain, while maximizing clinical
benefit.
ANTIEPILEPTIC DRUG STUDIES IN HUMANS
CARBAMAZEPINE
No effect of fetal carbamazepine exposure on IQ was reported in a
prospective, observational, evaluator-blinded study with matched
controls (Scolnik et al., 1994). In a study of preschool children,
no adverse effects of fetal carbamazepine exposure were seen in
this population-based, longitudinal follow-up study (Wide et al.,
2002). No IQ difference was found in a retrospective, blinded study
controlling for maternal IQ in 52 children of women with epilepsy
(WWE) exposed to carbamazepine versus 80 unexposed children
(Adab et al., 2004). No difference in IQ was seen in 86 children of
WWE exposed to carbamazepine monotherapy versus 45 children
of WWE on no AED or 141 healthy control children in a prospec-
tive, population-based, blinded, observational study controlling
for maternal education (Gaily et al., 2004). When data from this
study were pooled with data from another prospective population-
based study, mental retardation occurred in only 1 of 84 children
exposed to polytherapy (Gaily et al., 1988, 2004). Again, no IQ dif-
ference was seen in children of WWE exposed to carbamazepine
versus no AED in a population-based, evaluator-blinded study
(Eriksson et al., 2005). Evaluation on autism spectrum disorders
in 80 children exposed to carbamazepine monotherapy showed no
difference in frequency from the general population in a retrospec-
tive population-based study (Rasalam et al., 2005). In a prospective
observational multicenter study at ages 3 and 4.5 years, children
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exposed in utero to carbamazepine did not differ from lamotrigine
or phenytoin, however, they had better IQ outcomes than valproate
(Meador et al., 2009, 2012). Follow-up investigations showed fetal
exposure to carbamazepine as well as lamotrigine, phenytoin, and
valproate were associated with a reduction in verbal compared to
non-verbal abilities at age 3 and 4.5 years (Meador et al., 2011,
2012). This finding requires replication in separate cohorts to
determine if language abilities are particularly susceptible to fetal
AED exposure.
LAMOTRIGINE
Children exposed in utero to lamotrigine at ages 3 and 4.5 years
did not differ from those exposed to carbamazepine or pheny-
toin, but had better IQ outcomes than those exposed to valproate
at age 3 and 4.5 years in a prospective observational multicenter
study (Meador et al., 2009, 2012). In a follow-up investigation in
the same cohort, dose-related effects on verbal and non-verbal
cognitive measures were assessed in fetal AED exposed 3-year-
old children (Meador et al., 2011). This investigation set out
to ascertain whether differential long-term neurodevelopmental
effects exist across four commonly used AEDs (valproate, carba-
mazepine, lamotrigine, and phenytoin). The Differential Ability
Scales, Preschool Language Scale, Peabody PictureVocabulary Test,
and Developmental Test of Visual-Motor Integration were utilized
to calculate cognitive outcomes in 216 children. Children exposed
in utero to each drug exhibited lower verbal abilities than non-
verbal. A dose effect was not seen for lamotrigine or phenytoin at
age 3 (Meador et al., 2011).
LEVETIRACETAM
In a recent study comparing levetiracetam, valproate, and a control
group at less than age 24 months, children exposed to levetirac-
etam obtained higher developmental scores compared with chil-
dren exposed to valproate (n= 51 levetiracetam; n= 44 valproate;
p< 0.001). The levetiracetam group did not differ from the con-
trol group (n= 97; p= 0.62; Shallcross et al., 2011). Limitations
of the study included young age at assessment, retrospective data
for seizures and alcohol/tobacco use, and completer rates of only
37% for valproate and 58% for levetiracetam. Given these limita-
tions and the fact that this is the only study on neurodevelopment
effects of levetiracetam, caution should be exercised when utilizing
this source for clinical application. Replication of the findings is
needed.
PHENOBARBITAL
No difference in IQ was seen in 35 children of WWE exposed
in utero to phenobarbital monotherapy versus 4,705 children of
mothers without epilepsy according to a study done in Shapiro
et al. (1976). In contrast, two studies found approximately 0.5
SD lower verbal IQ scores in the men exposed to phenobarbital.
These studies involved separate cohorts of 114 adult men of moth-
ers without epilepsy, exposed in utero to phenobarbital (Reinisch
et al., 1995). It has also been shown that young children exposed
to phenobarbital have statistically different IQ scores than control
groups. One investigation of phenobarbital exposure in young
children with febrile seizures offers insights into the effects of phe-
nobarbital on the immature brain. A total of 217 children with
febrile seizures were randomized to a phenobarbital group or a
placebo group, and tested 2 years later; those exposed to pheno-
barbital had lower IQ (Farwell et al., 1990). If possible, avoidance
of phenobarbital in WWE during pregnancy, may be considered
to reduce the risk of poor cognitive outcomes (Harden et al.,
2009).
PHENYTOIN
No effect of fetal phenytoin exposure on IQ was seen in two
prospective, blinded, population-based studies that controlled for
socioeconomic class or maternal educational level (Shapiro et al.,
1976; Gaily et al., 1988). Another study using the same design but
drawn from a different patient pool demonstrated lower IQ at age
7 years in children of WWE exposed to phenytoin versus healthy
control children of mothers without epilepsy (Hanson et al., 1976).
Slightly lower scores for locomotor development were reported in
phenytoin-exposed children versus fetal carbamazepine-exposed
children and unexposed children in a population-based longitu-
dinal follow-up study of preschool children (Wide et al., 2002).
Phenytoin-exposed children had significantly lower IQ scores in a
blinded-evaluator, case–control study (Vanoverloop et al., 1992).
One prospective, blinded observational study demonstrated lower
IQ for children with fetal phenytoin exposure compared with
matched control (Scolnik et al., 1994), however no effect was seen
when maternal IQ was taken into consideration (Loring et al.,
1994). In a recent prospective observational multicenter stud-
ies of monotherapy, children at age 3 and again at age 4.5 years
exposed to phenytoin in utero had better IQ outcomes than those
exposed to valproate but did not differ from those exposed to
carbamazepine or lamotrigine (Meador et al., 2009, 2012). The
AAN recommended avoiding phenytoin in WWE during preg-
nancy based on level C evidence (Harden et al., 2009), however
more conclusive determinations on the risks of phenytoin will
require additional studies.
VALPROATE
Two prospective, population-based, evaluator-blinded studies in
children of WWE exposed in utero to valproate monotherapy
compared with children with carbamazepine monotherapy or no
AED exposure demonstrated lower verbal IQ or full-scale IQ in
the valproate group (Gaily et al., 2004; Eriksson et al., 2005).
Unfortunately, these studies are limited by the sample size of
the valproate monotherapy group (n= 26 across the two stud-
ies). Additionally, the studies revealed significantly lower maternal
education or IQ in the valproate group compared with other
WWE, which could have confounded the results. One retro-
spective study showed an increased need for special education
in children exposed to valproate monotherapy compared with
other monotherapies or the unexposed group (Adab et al., 2001).
Another large retrospective investigation from the same center,
which controlled for maternal IQ, demonstrated lower verbal
IQ (about 10 points) in children exposed in utero to valproate
(n= 41) versus other monotherapy groups and an unexposed
group (Adab et al., 2004). The decrease in IQ in the valproate
group was dose-dependent.
A prospective, observational, evaluator-blinded, multicenter
study, which enrolled pregnant WWE on AED monotherapy
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controlling for a variety of potential confounding factors including
maternal IQ, showed children exposed in utero to valproate had
lower IQ at ages 3 (7–9 points) and 4.5 (8–11 points) years com-
pared with other AEDs (carbamazepine, lamotrigine, or pheny-
toin; Meador et al., 2009, 2012). The detrimental effect of valproate
on IQ was dose-dependent. According to another analysis of the
same cohort, children exposed in utero to valproate monotherapy
had reduced verbal and non-verbal cognitive outcomes versus car-
bamazepine, lamotrigine, and phenytoin. The impact of valproate
appeared greater on verbal than non-verbal abilities, and the effect
was dose-dependent (Meador et al., 2011).
In another prospective study, the early cognitive development
of children of WWE (n= 198) was compared to general popula-
tion controls (n= 230). Children under 2 years old were assessed
by a blinded-evaluator using the Griffiths Mental Development
Scales. There was a statistically significant increased risk of delayed
early development in the group exposed to valproate compared
to controls. Children exposed to carbamazepine or lamotrigine
in utero did not differ from the control group (Bromley et al.,
2010).
An observational cohort study was conducted in children from
Northern Ireland aged 9–60 months born to mothers enrolled in
the UK Epilepsy and Pregnancy Register (Cummings et al., 2011).
Neurodevelopment was evaluated using either the Bayley Scales of
Infant Development or the Griffiths Mental Development Scales.
210 children were assessed by a single researcher blinded to AED
exposure. There was evidence of mild or significant developmen-
tal delay in 23 (39.6%) children exposed in utero to valproate, 10
(20.4%) exposed to carbamazepine, and 1 (2.9%) exposed to lam-
otrigine compared to two (4.5%) children in the control group.
Multivariable analysis demonstrated that in utero exposure to val-
proate (OR 26.1, 95% CI 4.9 to 139; p< 0.001) and carbamazepine
(OR 7.7, 95% CI 1.4 to 43.1; p< 0.01) had a significant detrimen-
tal effect on neurodevelopment, but no adverse effects were seen
for lamotrigine.
A recent study from Australia (Nadebaum et al., 2011), eval-
uated IQ in school-aged children exposed to valproate and
polytherapy during pregnancy (using the Wechsler Intelligence
Scale for Children – fourth edition). The results suggested that
there is a dose-dependent negative impact on verbal intellec-
tual abilities in the group exposed to valproate, and that val-
proate may also affect working memory. Additionally, the pos-
sibility that inclusion of valproate in polytherapy regimens may
underlie reduced mean scores was discussed (Nadebaum et al.,
2011).
One prospective and two retrospective studies have reported
an increased risk for autistic spectrum disorder or behavioral
abnormalities in valproate-exposed children (Rasalam et al., 2005;
Bromley et al., 2008; Vinten et al., 2009). Avoiding valproate in
WWE during pregnancy, if possible, should be considered to
reduce the risk of poor cognitive and verbal outcomes (Harden
et al., 2009).
BENZODIAZEPINES
The risks of fetal exposure from benzodiazepines to cognition and
behavior are unknown secondary to a dearth of adequate data in
human studies.
OTHER ANTIEPILEPTIC DRUGS
The risks of fetal exposure from other AEDs to cognition and
behavior are unknown secondary to a dearth of adequate data in
human studies.
POLYTHERAPY
According to one prospective study done in the 1970s (Shapiro
et al., 1976), no difference in IQ was noted among children
exposed to phenytoin and phenobarbital polytherapy versus other
children of WWE. However, subsequent prospective studies have
found otherwise. Children exposed to AED polytherapy in utero
had lower cognitive scores than healthy controls and children of
WWE exposed to monotherapy (Losche et al., 1994). Another
study showed children exposed in utero to AED polytherapy
had impaired verbal and non-verbal IQ compared with children
exposed to monotherapy (Koch et al., 1999; Gaily et al., 2004). A
recent population-based study utilized The Swedish School Mark
Registry to evaluate the long-term neurodevelopmental effects
of children of WWE exposed to AEDs in utero (Forsberg et al.,
2011). Data was obtained about school performance from the last
year of compulsory school, at age 16. Medical records of 1,235
children were analyzed. 641 children had AED exposure in utero
in monotherapy, 429 in polytherapy, and 165 no known AED.
School grades in four subjects were analyzed: sports, math, Eng-
lish, and Swedish. For each subject grades were in four groups: no
grade (which means that the child had not attended the lectures
in that subject enough to get a grade), not passed, passed, and
passed with excellence. Children born to WWE had a decreased
chance of getting a “pass with excellence.” The monotherapy
group, mainly those exposed to carbamazepine or phenytoin, did
not have a significantly increased risk of not receiving a final grade
(OR= 1.10; 95% CI 0.79–1.80). Notably, the polytherapy group
had an increased risk of not receiving a final grade [i.e., graduat-
ing; OR= 2.99; 95% confidence interval (CI) 2.14–4.17; Forsberg
et al., 2011]. If possible, AED polytherapy should be avoided in
WWE to reduce the risk of poor cognitive and verbal outcomes.
However, the risk of polytherapy combinations comprised of the
newer AEDs is unknown.
SEVERITY OF SEIZURE DISORDER
In WWE, the severity of the seizure disorder, including whether
or not a patient’s particular seizures are generalized tonic-clonic
seizures, could confer increased risk to the fetus for adverse out-
comes. Of necessity, this leads to use of higher doses of AEDS
and even polytherapy during pregnancy. In turn, this could lead
to increased risk for cognitive deficit. However, even though the
severity of the seizure disorder can affect fetal outcome, the effects
of AEDs on the child’s cognitive outcome cannot be explained by
this factor as it was assessed in the analysis for the Neurodevelop-
mental Effects of Antiepileptic Drugs (NEAD) study. One study
reported that >5 convulsions reduced cognitive outcomes (Adab
et al., 2004), but additional research is needed.
COMPARISON OF ANIMAL AND HUMAN STUDIES
Antiepileptic drugs can produce both anatomical (i.e., major con-
genital malformations, MCMs) or behavioral (i.e., cognitive) ter-
atogenicity in humans. The exact mechanisms are uncertain, but
www.frontiersin.org December 2012 | Volume 3 | Article 182 | 3
Gedzelman and Meador AED neurodevelopmental effects
current hypotheses include folate deficiency, ischemia, neuronal
suppression, reactive intermediates (e.g., free radicals or epoxides),
and AED-induced neuronal apoptosis with associated dysfunction
in surviving neurons (Meador et al., 2011). Because the high-
est risk of MCMs is from first-trimester AED exposure, but the
highest risk of behavioral defects appears to be primarily from
third-trimester exposure, it seems reasonable to assume that the
mechanisms underlying anatomical and behavioral teratogenesis
are probably different.
The leading hypothesis for the mechanism behind behav-
ioral/cognitive dysfunction involves AED-induced apoptosis and
associated dysfunction in surviving neurons. Genetic predisposi-
tion likely plays a role and could involve interaction of teratogens
with multiple-liability genes (Finnell et al., 1987). This, in part,
may explain the observed individual variability.
In animal studies, alcohol has been shown to produce wide-
spread neuronal apoptosis subsequently leading to neurobehav-
ioral deficits in the developing brain (Ikonomidou et al., 2000).
Neuronal dysfunction is also found in the remaining neurons
(Medina et al., 2003). The neurotoxic effects of ethanol on the
human fetal brain (i.e., fetal alcohol syndrome) have been recog-
nized for almost four decades. Of note, a single episode of ethanol
exposure of several hours duration can trigger a massive wave of
apoptotic neurodegeneration in the developing rat or mouse brain
(Olney et al., 2002). The window of vulnerability coincides with
the developmental period of synaptogenesis, which is estimated in
humans to occur from the sixth month of gestation to several years
after birth (the so-called brain growth-spurt period).N -methyl-d-
aspartate (NMDA) antagonist and gamma-aminobutyric (GABA)
mimetic traits of ethanol may be responsible for its apoptogenic
action, as other drugs that block NMDA glutamate receptors or
mimic GABA at GABA(A) receptors also trigger apoptosis in the
developing brain. This is clinically significant because many agents
used therapeutically in humans have NMDA antagonist or GABA
mimetic properties including barbiturates, benzodiazepines, and
many other anticonvulsants (Olney et al., 2002).
Fetal alcohol syndrome is a major cause of neurodevelopmen-
tal deficits. These deficits may result from disruption of neuronal
plasticity and neocortex development. During the third-trimester
equivalent of human gestation, alcohol exposure may have severe
and enduring consequences on sensory processing and learn-
ing as this is when the functional properties and connectivity of
neocortical neurons start to develop. One study used the monoc-
ular deprivation model of neural plasticity in ferrets, as it shares
many common mechanisms with learning (Medina et al., 2003).
This study demonstrated that a brief period of alcohol exposure
during development in the immature brain impairs ocular dom-
inance plasticity later in the ferrets’ life. This model provides a
novel approach to investigate and elucidate how alcohol disrupts
neural plasticity (Medina et al., 2003). In addition, ferrets were
exposed to alcohol on alternate days for 3 weeks leading to discon-
tinuous levels of blood alcohol that still induced reduced cortex
plasticity. This suggests that reduced cortex plasticity could be
due to a peak dose effect and not just a continuous effect of
total alcohol exposure. As mentioned above, a single episode of
ethanol exposure of several hours duration can trigger a mas-
sive wave of apoptotic neurodegeneration in the developing rat or
mouse brain (Olney et al., 2002). So, it follows that neuronal dys-
function may be present in some of the residual neurons even
after a single exposure. Evidence for the importance of peak
versus total exposure for AEDs has been seen in preliminary
animal data (see below), but has yet to be addressed in human
studies.
Recent animal testing has focused primarily on apoptosis; now
there is need for more cognitive and physiological testing in ani-
mals to parallel studies in humans. One of the first studies to assess
the effects of AEDs in animals for behavioral changes was done
in Vorhees (1985), which evaluated behavioral teratogenicity in
rats using multiple AEDs including diphenylhydantoin, trimetha-
dione, and phenobarbital. Another landmark animal study done
in Phillips and Lockard (1993) demonstrated that infant pri-
mates exposed to phenytoin, in monotherapy or in polyther-
apy with stiripentol led to increased risk for hyperexcitability
(screeching, refusing to attend to stimuli, lack of visual orien-
tation). In another study by the same investigators, they found
that infant monkeys exposed to carbamazepine monotherapy
or carbamazepine+ stiripentol polytherapy did not demonstrate
increased risk for hyperexcitability (Phillips and Lockard, 1996).
These trailblazing studies are of paramount importance because
they provide an early example of an approach to assessment of
behavioral teratogenesis of AEDs in animal models. Further, they
informed and inspired subsequent investigations in humans. More
studies in this vein would allow us to draw parallels between the
animal and human exposures to AEDs and thus direct therapy
more appropriately in humans.
The findings of alcohol-induced apoptosis in fetal animal brain
led to the use of the apoptotic model in studies with AEDs in
neonatal rats. Neonatal rats have been used in AED studies because
their developmental period parallels the human third-trimester
developmental period. Thus, this model is likely to reflect the sus-
ceptibility period to AEDs’ adverse effects in humans. AEDs that
have been shown to produce widespread neuronal apoptosis in
the neonatal rat brain include phenytoin, vigabatrin, valproate,
clonazepam, diazepam, and phenobarbital (Bittigau et al., 2002,
2003; Asimiadou et al., 2005; Stefovska et al., 2008; Ikonomi-
dou and Turski, 2010). The effect can occur with single dose
exposure, is dose-dependent, and occurs at therapeutically rel-
evant blood levels. Further, two of these AEDs given at below
threshold dosages, can still trigger the full apoptotic response,
suggesting a synergistic effect. Additionally, it is evident that
valproate induces neuronal apoptosis at blood levels which are
relatively lower in regards to valproate’s therapeutic range com-
pared to other AEDs (Bittigau et al., 2003). This may explain
why cognitive deficits are seen more commonly in humans after
fetal exposure to valproate. Some AEDs that do not produce
apoptosis in monotherapy can enhance apoptosis induced by
another AED (Katz et al., 2007). These include topiramate, car-
bamazepine, or lamotrigine (Glier et al., 2004; Manthey et al.,
2005; Kim et al., 2007). This suggests that polytherapy could
increase the risk. Levetiracetam is the only AED of those tested to
date that does not produce apoptosis in monotherapy or enhance
apoptosis of other AEDs (Manthey et al., 2005). Unfortunately,
most AEDs have not been tested in this model. Animal experi-
ments like these naturally raise a red flag that some commonly
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utilized AEDs could have similar adverse effects in children of
WWE exposed in utero or as neonates, however, clinical stud-
ies are needed to confirm if similar effects occur in the human
brain.
Antiepileptic drugs target neurotransmitters, ion channels,
and second messenger systems in the brain. These targets regu-
late processes essential not only for propagation of seizures but
for learning, memory, emotional behavior, and brain develop-
ment. The mechanisms that explain adverse effects of AEDs are
not fully understood but include interference with neurogenesis,
axonal arborization, synaptogenesis, cell proliferation and migra-
tion, synaptic plasticity, and apoptosis (Ikonomidou and Turski,
2010).
Antiepileptic drugs alterations to neurotransmitter systems
could potentially induce teratogenesis. This can disrupt both
neuronal migration and proliferation. Some AEDs can inhibit
glutamate action, e.g., topiramate and felbamate. GABA ago-
nists include phenobarbital, benzodiazepines, and valproate. The
neurotransmitter medium in the developing brain plays a large
role in the regulation of neuronal differentiation and migra-
tion. Based on animal studies, enhanced GABA inhibition and
blockade of NMDA receptors impairs neurogenesis and cell
migration (Manent et al., 2007; Stefovska et al., 2008). This can
lead to cortical dysplasias and reduced brain volume. Enhanced
GABA activity (Wong and Wong, 2001) and drug-induced inhi-
bition of NMDA receptor activity (Ogura et al., 2002) can
also disrupt synaptogenesis. In children exposed in utero to
AEDs, these neurotransmitter changes and resultant cellular
changes may account for impaired cognition (Palac and Meador,
2011).
Antiepileptic drugs alterations of genetic factors could affect
plasticity-related genes as a possible mechanism leading to behav-
ioral teratogenesis. One study (Roullet et al., 2010) addressed
this in a model where mouse pups were exposed in utero to val-
proate. Physical development, olfactory discrimination, and social
behavior was measured. The exposure resulted not only in motor
and sensory deficits, but dysfunctional social behavior as well.
Brain derived neurotrophic factor (BDNF) and NMDA recep-
tor subunits NR2A and NR2B were assessed. In situ hybridiza-
tion revealed lower cortical expression of BDNF mRNA in the
valproate-exposed animals. The results suggest that alterations
in plasticity-related genes may lead to this behavioral pheno-
type. Further, valproate-treated mice displayed physical devel-
opment delays, behavioral abnormalities, and modifications at
the level of gene expression reported in autism. This find-
ing opens up the possibility to examine specific factors like
BDNF in the development of autistic-related traits (Roullet et al.,
2010).
It may well be that dysfunction in the surviving neurons con-
tributes in a greater fashion to impaired cognition than neuronal
apoptosis itself; for example, young children suffering infantile
hemiplegia can develop normal language function despite severe
abnormalities in their dominant hemisphere because of normal
plasticity in the remaining non-dominant hemisphere. In fact, a
recent animal study (Forcelli et al., 2012a) demonstrated that expo-
sure to AEDs during a sensitive postnatal period impairs synaptic
maturation in neurons that survive the initial drug exposure. This
suggests a mechanism by which early AED exposure can lead to
impaired cognitive and behavioral outcomes and alerts us to the
necessity of identifying therapies that control seizures but do not
compromise synaptic maturation.
NEEDED FUTURE RESEARCH
Five areas for future research are highlighted.
1. ADDITIONAL AED TESTING
All AEDs need to be tested in animal models as well as in human
investigations. Future research needs to link animal and human
studies more effectively. Morphological changes as well as func-
tional deficits in animals should be related to human outcomes
to better understand how animal data can guide investigations in
humans and the use of AEDs in treatment of women of childbear-
ing age. As mentioned before, recent animal testing has focused
primarily on apoptosis; now there is need for more cognitive and
physiological testing in animals to parallel studies in humans.
More studies of this type are needed similar to the early inves-
tigations assessing the effects of AEDs in animals for behavioral
changes (Vorhees, 1985). Of note, early investigations such as the
one mentioned above provided the chief impetus for the genesis
of the ongoing NEAD study in humans.
A recent animal study on the long-term impact of AED expo-
sure during brain development examined phenobarbital, pheny-
toin, and lamotrigine (Forcelli et al., 2012b). Neonatal AED expo-
sure resulted in adult deficits in spatial learning in the Morris
water maze and decreased social exploration for all three AEDs.
However, there were a range of different deficits particular to each
drug seen in addition to the shared deficit. These results suggest
that AED exposure during a small window in the neonatal period
is enough to lead to a range of behavioral deficits later in life.
Additionally, the variance of subsequent behavioral deficits seen
across the three drugs in this study suggests that the specific profile
of behavioral deficits varies across AEDs. Of note, the behavioral
differences seen across these three AEDs were not predicted by
each drug’s mechanism of action nor by the proapoptotic effect
of the drugs. The findings suggest that AED exposure during the
early developmental period of humans should be viewed as a risk
factor for impaired cognitive and psychiatric outcomes later in
life. Investigations in humans are limited to only a few AEDs.
Additional studies are needed to establish the long-term effects
of fetal AED exposure across a range of cognitive and behavioral
domains.
2. AED POLYTHERAPY
The impact of polytherapy including specific combinations on
cognitive outcomes is unclear. Polytherapy for both older and
newer AEDs needs to be systematically evaluated in animals and
humans.
3. PHARMACOKINETICS DURING PREGNANCY
There is very limited data in humans regarding AED blood lev-
els and AED clearance during pregnancy. Clearance variability in
pregnancy may result in increased risk for seizures that could have
detrimental effects on the mother and fetus. Further differences in
AED blood levels may affect risk for behavioral deficits since ter-
atogens typically act in a dose-dependent manner. In humans,
www.frontiersin.org December 2012 | Volume 3 | Article 182 | 5
Gedzelman and Meador AED neurodevelopmental effects
AED blood levels should be tested for different AEDs and for
different polytherapies.
4. GENETICS
Teratogens act on a susceptible genotype. This may explain much
of the individual variability observed after fetal AED exposure
(Finnell et al., 1987). An understanding of the underlying genetic
risk factors could lead to improved prediction of risks. Further,
such knowledge could suggest potential avenues for treatments to
prevent or reverse adverse AED effects.
5. PREVENTIVE OR AMELIORATING THERAPIES
A better understanding of the mechanisms underlying the
observed AED effects is needed in order to develop ways to
block the effects of AEDs on the immature brain and to treat
the child after deficits have already occurred. Some possibili-
ties of future treatments could include vinpocetine that has been
shown to improve neuronal plasticity in rats, or estradiol that may
ameliorate neurotoxicity of some of the AEDs (see below).
Because the vulnerability of the immature brain to AED effects
likely extends beyond birth in humans and since AEDs are used in
neonates to treat seizures, studies are needed to examine the risks of
neonatal AED exposure. Pharmacological blockade of NMDA or
activation of GABA(A) receptors, blockade of voltage-dependent
sodium channels, and oxygen-induced widespread apoptotic neu-
rodegeneration during the so-called brain growth-spurt period in
rodents. Because such measures are often necessary in pregnant
WWE, as well as infants and toddlers, searching for adjunctive
neuroprotective strategies is warranted. AEDs have been shown
to reduce neurotrophins and signal proteins for cell growth. 17
β-estradiol is a neurotrophin and ameliorates neurotoxicity of
drugs that affect the infant rat brain in the fashion noted above.
17 β-estradiol and related compounds may be neuroprotective
agents suitable for use in the fetus and critically ill infants and tod-
dlers exposed to AEDs. Its supplementation may lead to improved
neurocognitive outcomes in these populations (Asimiadou et al.,
2005).
Vinpocetine (ethyl apovincaminate) discovered during the late
1960s has been used in the treatment of central nervous sys-
tem disorders of cerebrovascular origin. The increase in the
regional cerebral blood flow in response to vinpocetine adminis-
tration is well established. Vinpocetine is also a phosphodiesterase
type 1 inhibitor, which has been shown to enhance long-term
potentiation and improve memory in animal models (Filgueiras
et al., 2010). Vinpocetine also has anticonvulsive properties (Sit-
ges et al., 2011). Could this medication be applied to treat
the cognitive deficits seen from fetal alcohol syndrome or AED
exposure?
Alcohol exposure in the immature brain leads to a persistent
disruption in ocular dominance plasticity in an animal model.
Using a combination of electrophysiological and optical imaging
techniques, one animal study showed that vinpocetine, restores
ocular dominance plasticity in the ferret model of fetal alcohol
exposure (Medina et al., 2006). This finding could contribute to
a possible treatment of cognitive deficits associated with cogni-
tive disorders such as fetal alcohol syndrome in humans. Another
study done in Paul and Medina (2012) using the ocular dominance
ferret model showed that the plasticity deficit can be reversed if
the previously alcohol-exposed animals are treated with a therapy
that has similar effects to the downstream effects of a phospho-
diesterase inhibitor like vinpocetine. Vinpocetine’s mechanism
of action is thought to act by inhibition of phosphodiesterase
type 1 and may increase cAMP and cGMP levels, activating
transcription factors such as the cAMP response element bind-
ing protein (CREB) and the serum response factor (SRF). SRF
is important for many plasticity processes such as long-term
potentiation, long-term depression, spine motility, and axonal
pathfinding Immature ferrets were exposed to alcohol and later
treated during the period of monocular deprivation using a Sind-
bis viral vector to express a constitutively active form of SRF in
astrocytes. Using single-unit recordings and optical imaging of
intrinsic signals, the investigators found that overexpression of
a constitutively active form of SRF restored ocular dominance
plasticity in the alcohol-treated animals. This finding suggests
that overexpression of SRF may reduce the deficits in neuronal
plasticity seen in models of fetal alcohol syndrome. It there-
fore follows that a medication like vinpocetine that has down-
stream upregulation of SRF may have the same effect on neuronal
plasticity.
A study in rats supports the ability of vinpocetine to reverse
alcohol-induced deficits (Filgueiras et al., 2010). The Morris maze
test was used to assess whether vinpocetine restores learning per-
formance in rats exposed to alcohol during the third-trimester
equivalent of human gestation. Early alcohol exposure signifi-
cantly affected the performance to find the hidden platform as
the ethanol-exposed rats took significantly longer than the con-
trol group. However, when the alcohol-exposed animals were
treated with vinpocetine their performance was restored to con-
trol levels. The results show evidence for the potential therapeutic
use of vinpocetine in fetal alcohol syndrome and suggest that
a phosphodiesterase type 1 inhibitor can improve learning and
memory deficits in rats exposed early to alcohol (Filgueiras et al.,
2010).
SUMMARY
Animal studies have demonstrated that exposure of the immature
brain to AEDs can produce neuronal apoptosis, impair physiology
in surviving neurons, and result in reduced cognitive outcomes.
However, only a limited number of AEDs have been tested in these
animal models. There are no human studies examining the effects
of fetal AED exposure on neuronal apoptosis and electrophysiol-
ogy of the remaining neurons. Human studies have demonstrated
impaired cognitive outcomes in children exposed in utero to val-
proate, which occurs in a dose-dependent manner. There is some
human data providing evidence for adverse cognitive effects of
phenobarbital and for absence of major adverse effects for car-
bamazepine, lamotrigine, and levetiracetam. Evidence for other
AEDs is inconclusive or non-existent in humans.
Even in animals, the full extent of mechanisms are poorly
understood. Our knowledge in humans is very inadequate in
regards to the reasons for individual variability, the exact develop-
mental window of vulnerability to AEDs after birth, and potential
approaches to blocking or mediating adverse effects. Thus, there
are many areas that critically require additional research.
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